Solid forms of an antiviral compound
US9682987B2 · kind B2 · utility
2Cited by
4References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 13, 2015 |
| Grant date | Jun 20, 2017 |
| Priority date | — |
| Expiry date | Sep 18, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state:Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.